Robert S Hargesheimer Net Worth

The estimated Net Worth of Robert S Hargesheimer is at least $4.03 Milhão dollars as of 29 November 2007. Robert Hargesheimer owns over 13,375 units of West Pharmaceutical Services stock worth over $3,525,401 and over the last 17 years Robert sold WST stock worth over $508,116.

Robert Hargesheimer WST stock SEC Form 4 insiders trading

Robert has made over 1 trades of the West Pharmaceutical Services stock since 2007, according to the Form 4 filled with the SEC. Most recently Robert sold 13,375 units of WST stock worth $508,116 on 29 November 2007.

The largest trade Robert's ever made was selling 13,375 units of West Pharmaceutical Services stock on 29 November 2007 worth over $508,116. On average, Robert trades about 1,672 units every 0 days since 2007. As of 29 November 2007 Robert still owns at least 11,660 units of West Pharmaceutical Services stock.

You can see the complete history of Robert Hargesheimer stock trades at the bottom of the page.

What's Robert Hargesheimer's mailing address?

Robert's mailing address filed with the SEC is 101 GORDON DRIVE, , LIONVILLE, PA, 19341.

Insiders trading at West Pharmaceutical Services

Over the last 19 years, insiders at West Pharmaceutical Services have traded over $32,829,857 worth of West Pharmaceutical Services stock and bought 19,924 units worth $1,139,950 . The most active insiders traders include Robert F Friel, Paolo Pucci, eDouglas A Michels. On average, West Pharmaceutical Services executives and independent directors trade stock every 40 days with the average trade being worth of $4,786,805. The most recent stock trade was executed by Charles Witherspoon on 19 August 2024, trading 1,029 units of WST stock currently worth $308,700.

What does West Pharmaceutical Services do?

west works side-by-side with healthcare partners from concept to the patient, designing and manufacturing packaging and delivery systems that promote efficiency, reliability and safety. west leads the way with cutting-edge technologies and quality systems, a thorough understanding of global regulatory compliance, and an unmatched knowledge of relevant pharmaceutical product testing, development and packaging. west supports customers from sales, manufacturing, and research and development locations in north and south america, europe, asia and australia.

Complete history of Robert Hargesheimer stock trades at West Pharmaceutical Services

West Pharmaceutical Services executives and stock owners

West Pharmaceutical Services executives and other stock owners filed with the SEC include:

• Eric Green,
  President, Chief Executive Officer, Director
• Eric M. Green,
  Pres, CEO & Director
• Bernard Birkett,
  Chief Financial Officer, Senior Vice President
• George Miller,
  Senior Vice President, General Counsel, Corporate Secretary
• Bernard J. Birkett,
  Sr. VP & CFO
• Silji Abraham,
  Senior Vice President and Chief Digital and Transformation Officer
• David Montecalvo,
  Senior Vice President, Chief Operating and Supply Chain Officer
• Annette Favorite,
  Chief Human Resource Officer, Senior Vice President
• David A. Montecalvo,
  Sr. VP and Chief Operations & Supply Chain Officer
• Silji Abraham,
  Sr. VP & Chief Technology Officer
• Patrick Zenner,
  Independent Chairman of the Board
• Douglas Michels,
  Independent Director
• Thomas Hofmann,
  Independent Director
• Paula Johnson,
  Independent Director
• William Feehery,
  Independent Director
• Mark Buthman,
  Independent Director
• Myla Lai-Goldman,
  Independent Director
• Paolo Pucci,
  Independent Director
• Deborah Keller Tanner,
  Independent Director
• Chad Winters,
  Chief Accounting Officer, Principal Accounting Officer, Vice President, Controller
• Robert Friel,
  Independent Director
• Cindy Reiss-Clark,
  Senior Vice President of Global Market Units and Commercial Solutions
• Quintin Lai,
  Vice President - Corporate Development, Strategy and Investor Relations
• Eric Resnick,
  Chief Technology Officer, Vice President
• Richard D. Luzzi,
  Sr. VP of HR
• Annette F. Favorite,
  Chief HR Officer & Sr. VP
• Michele Polinsky,
  VP of Global Communications
• Kimberly Banks MacKay,
  Sr. VP, Gen. Counsel & Company Sec.
• Dr. Quintin J. Lai C.F.A., Ph.D.,
  VP of Strategy & Investor Relations
• Daniel Malone,
  Vice President & Controller
• William J Federici,
  VP & CFO
• John H Weiland,
  Director
• Karen Flynn,
  President, America's Region
• Heino Lennartz,
  President Europe
• Anthony Welters,
  Director
• Warwick Bedwell,
  VP Pharma Pkgs Systems Asia Pa
• John E Paproski,
  Vice President-Innovations
• Christopher G Ryan,
  President, PPS, Americas
• Rachael M Bushey,
  VP, Deputy Gen Coun & Corp Sec
• Jeffrey C Hunt,
  VP Pharma Pckg Systems
• John R Gailey,
  VP, Gen. Counsel & Sec.
• Richard D Luzzi,
  VP, Human Resourses
• L Robert Johnson,
  Director
• Michael A Anderson,
  Vice President & Treasurer
• Donald E Jr Morel,
  Chairman of the Board & CEO
• Robert C Young,
  Director
• Donald A Mc Millan,
  President Pharma Systems NA
• Steven A Ellers,
  Pres., Pharma. Systems Div.
• Geoffrey F Worden,
  Director
• John P Neafsey,
  Director
• Joseph E Abbott,
  Corporate Controller
• Dijk Ronald Van,
  President Asia Pacific
• Robert S Hargesheimer,
  President-The Tech Group
• Fabio De Sampaio Doria Filho,
  Pres., Europe & Asia Pacific
• Matthew T Mullarkey,
  Chief Operating Officer
• Robert J Keating,
  Pres., Europe & Asia Pacific
• Jenne K Britell,
  Director
• Herbert L Hugill,
  Pres. of the Americas, Pharma.
• Linda R Altemus,
  VP & Chief Compliance Officer
• Molly Joseph,
  Director
• Deborah L Keller,
  Director
• Stephen H Lockhart,
  Director
• Charles Witherspoon,
  VP & Treasurer
• Kimberly Banks Mac Kay,
  SVP, GC & Corporate Secretary